Human Papillomavirus Vaccination Acceleration and Introduction in Sub-Saharan Africa: A Multi-Country Cohort Analysis.

Autor:	Adeyanju GC; Center for Empirical Research in Economics and Behavioural Science (CEREB), University of Erfurt, 99089 Erfurt, Germany.; Psychology and Infectious Disease Lab (PIDI), University of Erfurt, 99089 Erfurt, Germany.; Media and Communication Science, University of Erfurt, 99089 Erfurt, Germany., Essoh TA; Agence de Médecine Préventive (AMP) Afrique, Abidjan 08 BP 660, Côte d'Ivoire., Sidibe AR; National Immunization Technical Advisory Groups (NITAGs), Ouaga 06, Ouagadougou 06 BP 9096, Burkina Faso., Kyesi F; Ministry of Health, S.L.P. 743, Dar es Salaam P.O. Box 9083, Tanzania., Aina M; Executive Secretary, National Primary Healthcare Development Agency (NPHCDA), Area 11, Abuja P.O. Box 123, Nigeria.
Jazyk:	angličtina
Zdroj:	Vaccines [Vaccines (Basel)] 2024 May 01; Vol. 12 (5). Date of Electronic Publication: 2024 May 01.
DOI:	10.3390/vaccines12050489
Abstrakt:	Background: Cervical cancer, caused by human papillomavirus (HPV) infection, is the second-largest cancer killer of women in low- and middle-income countries. The brunt of the global burden is borne predominantly in Sub-Saharan Africa. In 2020 alone, 70,000 of the 100,000 infected women in Africa died from it, thereby making up 21% of global cervical cancer mortality. The introduction of the HPV vaccine into the National Immunization Program was expected to change the trajectory. However, uptake of the vaccination has been poor, especially for the second dose. Only about half of the countries in Africa currently provide the vaccine. Without urgent intervention, the 2030 global cervical cancer elimination targets will be undermined. The study aims to understand the key challenges facing the HPV vaccine and to develop a roadmap to accelerate the uptake. Method: Fourteen countries were purposively included using a cohort design methodology and the investigation spanned March-July 2023. The Africa region was stratified into three focus-group discussion cohorts (Abidjan, Nairobi and Dar es Salaam), comprising pre-selected countries that have already and those about to introduce the HPV vaccine. In each country, the EPI manager, the NITAG chair or representatives and an HPV-focal researcher were selected participants. The methods involved a collaborative and knowledge-sharing format through regional and country-specific discussions, plenary discussions, and workshop-style group missions. Results: The study reached a total of 78 key stakeholders, comprising 30 participants in cohort one, 21 in cohort two and 27 in cohort three. Key outcomes included the prevalence of declining HPV2 vaccination across all countries in the region; country-specific barriers impeding uptake were identified and strategy for accelerating vaccination demand initiated, e.g., utilizing investments from COVID-19 (e.g., electronic registry and multisector coordination); individual countries developing their respective HPV vaccination recovery and acceleration roadmaps; the identification and inclusion of a zero-dose catch-up strategy into the vaccination roadmaps; support for a transition from multiple-doses to a single-dose HPV vaccine; the incorporation of implementation science research to support the decision-making process such as vaccine choices, doses and understanding behavior. Conclusion: Beyond research, the study shows the significance of scientific approaches that are not limited to understanding problems, but are also solution-oriented, e.g., development of roadmaps to overcome barriers against HPV vaccination uptake.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu